Julia Dorn

Ismaninger Str. 22
Munich, BY 81675, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

High uPAR and Low miR-221 Expression Predict Poor Disease-Free Survival in Triple-Negative Breast Cancer.

High uPAR and Low miR-221 Expression Predict Poor Disease-Free Survival in Triple-Negative Breast Cancer.

Journal: Pathophysiology : the official journal of the International Society for Pathophysiology

Published: February 06, 2026

Insights on the Current State and Future Outlook of AI in Health Care: Expert Interview Study.

Insights on the Current State and Future Outlook of AI in Health Care: Expert Interview Study.

Journal: JMIR AI

Published: March 16, 2023

Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer.

Association of high miR-27a, miR-206, and miR-214 expression with poor patient prognosis and increased chemoresistance in triple-negative breast cancer.

Journal: American journal of cancer research

Published: January 23, 2023

tRNA-derived small RNA 3'U-tRFValCAC promotes tumour migration and early progression in ovarian cancer.

tRNA-derived small RNA 3'U-tRFValCAC promotes tumour migration and early progression in ovarian cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 11, 2022

A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression.

A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression.

Journal: Life (Basel, Switzerland)

Published: August 26, 2022

Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer.

Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer.

Journal: Clinical biochemistry

Published: June 06, 2022

tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression.

tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression.

Journal: Cancers

Published: October 19, 2021

A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.

A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.

Journal: Annals of surgery

Published: November 06, 2020

Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.

Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.

Journal: American journal of translational research

Published: October 16, 2020

Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.

Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.

Journal: Journal of ovarian research

Published: July 21, 2020

High levels of KLK7 protein expression are related to a favorable prognosis in triple-negative breast cancer patients.

High levels of KLK7 protein expression are related to a favorable prognosis in triple-negative breast cancer patients.

Journal: American journal of cancer research

Published: May 03, 2020

The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer In Vitro and In Vivo.

The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer In Vitro and In Vivo.

Journal: Cancer immunology research

Published: April 23, 2020

Showing 1-12 of 40

Last Updated: 09/26/2026